BMO Capital Markets Raises Eli Lilly and Company (NYSE:LLY) Price Target to $1,001.00

Eli Lilly and Company (NYSE:LLY) had its price target raised by BMO Capital Markets from $900.00 to $1,001.00 in a research note released on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities research analysts have also recently weighed in on the stock. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a buy rating in a research report on Tuesday, April 2nd. DZ Bank downgraded Eli Lilly and Company from a buy rating to a hold rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a buy rating in a research report on Friday, March 1st. TheStreet raised Eli Lilly and Company from a c+ rating to a b rating in a research report on Friday, March 8th. Finally, Barclays increased their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an overweight rating in a report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $757.95.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $776.75 on Wednesday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a fifty-two week low of $399.26 and a fifty-two week high of $800.78. The firm has a market capitalization of $738.04 billion, a PE ratio of 114.40, a price-to-earnings-growth ratio of 1.58 and a beta of 0.37. The stock’s 50-day simple moving average is $762.03 and its 200-day simple moving average is $669.96.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.62 earnings per share. As a group, equities research analysts forecast that Eli Lilly and Company will post 13.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently added to or reduced their stakes in the company. Harbor Advisors LLC raised its stake in shares of Eli Lilly and Company by 80.0% during the 1st quarter. Harbor Advisors LLC now owns 900 shares of the company’s stock worth $700,000 after buying an additional 400 shares in the last quarter. Mckinley Capital Management LLC raised its position in Eli Lilly and Company by 10.5% in the first quarter. Mckinley Capital Management LLC now owns 18,654 shares of the company’s stock worth $14,512,000 after acquiring an additional 1,766 shares in the last quarter. Moloney Securities Asset Management LLC lifted its holdings in Eli Lilly and Company by 1.8% in the first quarter. Moloney Securities Asset Management LLC now owns 5,284 shares of the company’s stock valued at $4,110,000 after acquiring an additional 91 shares during the period. Rockline Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 25.2% during the 1st quarter. Rockline Wealth Management LLC now owns 2,540 shares of the company’s stock worth $1,976,000 after purchasing an additional 511 shares in the last quarter. Finally, Main Street Research LLC grew its stake in shares of Eli Lilly and Company by 4.8% during the 1st quarter. Main Street Research LLC now owns 3,281 shares of the company’s stock worth $2,552,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.